---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-002422"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2026-01-15T23:59:59+00:00"
generated_at: "2026-05-16T10:06:10.012476+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma grants stock options to directors, officers, and consultant under 2025 Plan

## Summary
- Non-qualified stock options granted to 7 directors, 2 executive officers, and 1 consultant, vesting over 1-2 years.
- Vesting: 50% on Jan 9, 2027; remaining 50% in 8 quarterly installments starting Mar 31, 2027.
- Dr. Roger Kornberg receives 24,615 options (plus $50,000 cash award for SAB chair); James Martin and Sam Lee each receive 49,229.
- Directors (excluding executives) each receive 16,410 options; consultant receives 40,000 options.
- Options have 10-year term, exercise price set at Jan 8, 2026 closing price.

## SEC filing metadata
- accession: 0001493152-26-002422
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2026-01-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315226002422/0001493152-26-002422-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315226002422/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-002422
- JSON: https://secwatch.observer/filing/0001493152-26-002422.json
- Plain text: https://secwatch.observer/filing/0001493152-26-002422.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.